Prevention of Cardiovascular Complications in Diabetic Patients With Vitamin E Treatment

Clinical Trial ID NCT00220831

Rank	Title	Journal	Year	PubWeight™‹?›
1	Haptoglobin phenotype and diabetic nephropathy.	Diabetologia	2001	2.27
2	Structure-function analysis of the antioxidant properties of haptoglobin.	Blood	2001	2.17
3	Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study.	J Am Coll Cardiol	2002	2.08
4	Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial.	Arterioscler Thromb Vasc Biol	2007	1.96
5	Haptoglobin genotype is a consistent marker of coronary heart disease risk among individuals with elevated glycosylated hemoglobin.	J Am Coll Cardiol	2013	1.85
6	Haptoglobin phenotype and vascular complications in patients with diabetes.	N Engl J Med	2000	1.23
7	The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes.	Diabetes Care	2004	1.18
8	Haptoglobin phenotype and coronary artery collaterals in diabetic patients.	Atherosclerosis	2002	1.13
9	Haptoglobin genotype as a risk factor for diabetic retinopathy.	JAMA	2000	0.89
10	Haptoglobin phenotype as a predictor of restenosis after percutaneous transluminal coronary angioplasty.	Am J Cardiol	2001	0.82